CMO Archives - PharmaLive

Pharma Poised for Continued Growth in 2021 Driven By Lessons Learned From COVID-19

Business, Clinical Trials, CMO, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, Current Goods and Manufacturing Practice (CGMP), Drug Prices, Innovation, Life Sciences, Orphan Drug Act, Pharma, R&D, Start-Ups, Trends

Jean-Noel David, Managing Director at Seqens CDMO NA, identifies six key trends that promise to reshape the pharma landscape during 2021 and beyond.

Pharma & Biotech 2017 – Review of outsourced manufacturing

Biologics, CMO, FDA/Regulatory, Forecasts, High Potency Active Pharmaceutical Ingredients (HPAPIs), Manufacturing, Pharma, Pharmaceutical Outsourced Manufacturing, White Papers

Overall, the prospects for the sector remain strong, linked to the expected growth in healthcare. There is a strong case for investment in particular segments, subject to appropriate valuation and due diligence. This report highlights some of the trends that should be in the minds of CEOs, CFOs and investors.

Bridging The Value Chain – The Pedigree Way

Big Pharma, Brazil, Chine, CMO, Contract Development Manufacturing Organization (CDMO), Counterfeiting, India, Packaging, Pharma, Serialization, South Korea, Technology, Turkey, White Papers

By Arun Ramesh, Lead Analyst, Beroe Inc. Abstract 1 Serialization – Need of the HourLack of global co-operation on agreement with one common technology over the years has delayed […]